Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dirceu Barbano reappointed director of Brazil’s Anvisa

This article was originally published in Clinica

Executive Summary

Dirceu Barbano has been reappointed as director of Brazilian healthcare regulatory agency Anvisa for a second three-year term. The priorities for the agency during his tenure will be to make it “more efficient without compromising on the rigour that characterises its decision-making”. This will be achieved by “improving the regulatory framework [and through] closer dialogue with society”, he told the Senate’s Social Affairs Commission (CAS), which gave final approval for the appointment. Mr Barbano, a pharmacist, originally joined Anvisa in October 2008, but has been serving as the agency’s director-president since January 2011, when the health ministry was restructured under the change of federal presidency (www.clinica.co.uk, 7 January 2011).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT097959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel